Celyad Oncology SA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 51

Market Cap: -

Website: http://www.celyad.com

Clinical Trials

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: CYAD-101
Drug: FOLFOX
Drug: Pembrolizumab

First Posted Date: 2021-08-05

Last Posted Date: 2022-03-09

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 34

Registration Number: NCT04991948

Locations: 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
UZ Gent, Ghent, Belgium

and more 2 locations

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Relapse/Refractory Multiple Myeloma

Interventions: Biological: CYAD-211
Drug: Endoxan
Drug: Fludara

First Posted Date: 2020-11-03

Last Posted Date: 2023-08-31

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 18

Registration Number: NCT04613557

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇺🇸
Nyu Langone Hospitals, New York, New York, United States

and more 2 locations

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Biological: CYAD-02
Drug: ENDOXAN
Drug: Fludara

First Posted Date: 2019-11-19

Last Posted Date: 2020-06-09

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 27

Registration Number: NCT04167696

Locations: 🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States
🇧🇪
Uz Leuven, Leuven, Belgium
🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States

and more 2 locations

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Phase 1

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: CYAD-101
Drug: FOLFOX
Drug: FOLFIRI

First Posted Date: 2018-10-02

Last Posted Date: 2020-11-20

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 49

Registration Number: NCT03692429

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇺🇸
Moffit Cancer Center, Tampa, Florida, United States
🇧🇪
Institut Jules Bordet, Brussels, Belgium

and more 1 locations

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2

Phase 1

Withdrawn

Conditions: AML, Adult
Myelodysplastic Syndromes

Interventions: Biological: NKR-2 CAR-T Cells

First Posted Date: 2018-08-02

Last Posted Date: 2019-10-29

Lead Sponsor: Celyad Oncology SA

Registration Number: NCT03612739

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

Phase 1

Completed

Conditions: MDS
AML

Interventions: Biological: NKR-2

First Posted Date: 2018-03-15

Last Posted Date: 2021-05-04

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 21

Registration Number: NCT03466320

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.,, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 4 locations

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Phase 1

Terminated

Conditions: Colon Cancer Liver Metastasis

Interventions: Biological: NKR-2 cells

First Posted Date: 2017-12-12

Last Posted Date: 2024-02-28

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 1

Registration Number: NCT03370198

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

Phase 1

Conditions: Colon Cancer Liver Metastasis

Interventions: Biological: NKR-2 cells

First Posted Date: 2017-10-16

Last Posted Date: 2020-06-16

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 36

Registration Number: NCT03310008

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium

and more 1 locations

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Phase 1

Conditions: Multiple Myeloma (MM)
Acute Myeloid Leukemia/Myelodysplastic Syndrome

Interventions: Biological: NKR-2 cells

First Posted Date: 2017-01-12

Last Posted Date: 2019-09-19

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 146

Registration Number: NCT03018405

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL

Phase 3

Conditions: Heart Failure

Interventions: Biological: Sham comparator
Biological: Experimental

First Posted Date: 2014-12-16

Last Posted Date: 2016-07-11

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 400

Registration Number: NCT02317458

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy